We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
801
LivaNova
LIVN
$4.47B
| $1.59M | ﹤0.01% |
25,850
-220,443
| -90% | -$12.6M |
|
802
Solventum
SOLV
$15.3B
| $1.51M | ﹤0.01% |
19,103
+224
| +1% | +$17.2K |
|
803
Skyworks Solutions
SWKS
$9.21B
| $1.51M | ﹤0.01% |
23,852
-3,854
| -14% | -$269K |
|
804
Independence Realty Trust
IRT
$3.98B
| $1.51M | ﹤0.01% |
86,103
+8,584
| +11% | +$142K |
|
805
Canadian Solar
CSIQ
$932M
| $1.46M | ﹤0.01% |
61,597
-16,134
| -21% | -$352K |
|
806
State Street SPDR S&P 500 ETF Trust
SPY
$771B
| $1.44M | ﹤0.01% |
2,117
| – | – |
|
807
APA Corp
APA
$13B
| $1.42M | ﹤0.01% |
58,238
-3,510
| -6% | -$84.9K |
|
808
AES
AES
$10.6B
| $1.41M | ﹤0.01% |
98,370
+49,969
| +103% | +$704K |
|
809
SL Green Realty
SLG
$3.83B
| $1.34M | ﹤0.01% |
29,317
-259,392
| -90% | -$12.8M |
|
810
Tanger
SKT
$4.78B
| $1.33M | ﹤0.01% |
39,998
-1,857
| -4% | -$61.9K |
|
811
Broadstone Net Lease
BNL
$4.25B
| $1.33M | ﹤0.01% |
76,787
+11,271
| +17% | +$203K |
|
812
Alcoa
AA
$11.3B
| $1.32M | ﹤0.01% |
24,925
+1,780
| +8% | +$72.8K |
|
813
Americold
COLD
$4.21B
| $1.32M | ﹤0.01% |
102,958
+4,768
| +5% | +$58.4K |
|
814
GlobalFoundries
GFS
$25.8B
| $1.32M | ﹤0.01% |
37,845
-552
| -1% | -$19.6K |
|
815
COPT Defense Properties
CDP
$4.32B
| $1.28M | ﹤0.01% |
46,204
+7,054
| +18% | +$203K |
|
|
JKS
816
JinkoSolar
JKS
$764M
| $1.28M | ﹤0.01% |
49,500
-12,965
| -21% | -$331K |
|
817
Match Group
MTCH
$9.19B
| $1.27M | ﹤0.01% |
39,297
-3,891
| -9% | -$128K |
|
818
Fiverr
FVRR
$331M
| $1.26M | ﹤0.01% |
63,836
-1,433
| -2% | -$30.9K |
|
819
Performance Food Group
PFGC
$18.3B
| $1.2M | ﹤0.01% |
13,351
-1,607
| -11% | -$155K |
|
820
iShares MSCI India ETF
INDA
$6.81B
| $1.19M | ﹤0.01% |
22,004
-41,418
| -65% | -$2.23M |
|
|
XRN
821
Chiron Real Estate Inc
XRN
$535M
| $1.18M | ﹤0.01% |
34,978
| – | – |
|
822
Century Aluminum
CENX
$4.22B
| $1.17M | ﹤0.01% |
29,822
+2,525
| +9% | +$78.9K |
|
823
Parsons
PSN
$4.31B
| $1.15M | ﹤0.01% |
18,559
-1,492
| -7% | -$117K |
|
824
A.O. Smith
AOS
$8.55B
| $1.15M | ﹤0.01% |
17,137
+10,433
| +156% | +$705K |
|
825
Albemarle
ALB
$13.4B
| $1.11M | ﹤0.01% |
7,844
+37
| +0.5% | +$4.2K |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.